Patent ID: 11951129
Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A chimeric antigen receptor (CAR) polypeptide, comprising a CLEC12A antigen binding domain, a transmembrane domain, an intracellular signaling domain, and a co-stimulatory signaling region,
wherein the CLEC12A antigen binding domain is a single-chain variable fragment (scFv) of an antibody that specifically binds CLEC12A,
wherein the CDR1 sequence of the VH domain comprises the amino acid sequence SEQ ID NO:1; the CDR2 sequence of the VH domain comprises the amino acid sequence SEQ ID NO:4 or SEQ ID NO:5; the CDR3 sequence of the VH domain comprises the amino acid sequence SEQ ID NO:8; the CDR1 sequence of the VL comprises the amino acid sequence SEQ ID NO:10; the CDR2 sequence of the VL domain comprises the amino acid sequence SEQ ID NO:13; and the CDR3 sequence of the VL domain comprises the amino acid sequence SEQ ID NO:15; or
wherein the CDR1 sequence of the VH domain comprises the amino acid sequence SEQ ID NO:2; the CDR2 sequence of the VH domain comprises the amino acid sequence SEQ ID NO:4; the CDR3 sequence of the VH domain comprises the amino acid sequence SEQ ID NO:8; the CDR1 sequence of the VL comprises the amino acid sequence SEQ ID NO:11; the CDR2 sequence of the VL domain comprises the amino acid sequence SEQ ID NO:13; and the CDR3 sequence of the VL domain comprises the amino acid sequence SEQ ID NO:15; or
wherein the CDR1 sequence of the VH domain comprises the amino acid sequence SEQ ID NO:3; the CDR2 sequence of the VH domain comprises the amino acid sequence SEQ ID NO:4 or SEQ ID NO:5; the CDR3 sequence of the VH domain comprises the amino acid sequence SEQ ID NO:9; the CDR1 sequence of the VL comprises the amino acid sequence SEQ ID NO:11; the CDR2 sequence of the VL domain comprises the amino acid sequence SEQ ID NO:13; and the CDR3 sequence of the VL domain comprises the amino acid sequence SEQ ID NO:15.